Trial Profile
A Single Dose Study to Assess the Effect of Non-Bioenhanced, Non-Enteric Coated, Freebase SB-659032 on Platelet Function in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Rilapladib (Primary)
- Indications Atherosclerosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 May 2015 New trial record